Eli Lily pausa el tratamiento con anticuerpos contra el coronavirus debido a problemas de seguridad

La compañía farmacéutica estadounidense dice que está pausando el ensayo de la vacuna 'por precaución'.

Donald Trump en conferencia de prensa.
Read in English

Un importante ensayo de anticuerpos para una posible vacuna Covid-19 se detuvo en Estados Unidos en medio de preocupaciones de seguridad, confirmó un portavoz de Eli Lilly.

El ensayo de anticuerpos monoclonales ACTIV-3, respaldado por la iniciativa de vacuna contra el coronavirus de la administración Trump denominada Operation Warp Speed , se suspendió "por precaución", según el portavoz.

La declaración decía: “La seguridad es de suma importancia para Lilly. Somos conscientes de que, por precaución, la junta de monitoreo de seguridad de datos (DSMB) independiente ACTIV-3 ha recomendado una pausa en la inscripción ".

Esta es una historia de última hora y se actualizará.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in